4DMedical
4DMedical is a medical technology company, based in Australia and the United States. 4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS) based on the Company’s proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography (CT) images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report. 4DMedical has commercialized its XV Technology via a Software as a Service (SaaS) model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Thus, treatment may be applied early to increase impact and outcomes. History Founded in 2013, 4DMedical commenced business as 4DX, started as a private company and listed on the Australian Securities Exchange Ltd. (ASX: 4DX) in August of 2020. Prior to founding 4DMedical, Dr. Andreas Fouras was a professor of Biomedical Engineering, and worked closely with the researchers from the Departments of Physics and Physiology at Monash University (Melbourne, Australia) to develop the underlying technology behind 4DMedical’s XV Technology. In 2005 Fouras conceptualized 4D imaging using X-rays and in 2009, the first patent for XV Technology was filed. Fouras and his colleagues adapted wind-tunnel imaging techniques used by engineers to develop a new technique that combines fluoroscopy and advanced visualization to generate high-resolution images of the motion of, and airflow through, lung tissue. XV Technology research has been documented in over 100 peer-reviewed publications and over 72 patents and patent applications. PACT Act and Lung Disease in Veterans Exposed to Burn Pits The PACT Act (Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022) was signed into U.S. law in 2022, and expands Veteran Affairs (VA) healthcare and benefits for previously deployed veterans who were exposed to burn pits and other toxic substances. 4DMedical has worked closely with advocacy groups such as Burn Pits 360 on difficult-to-diagnose lung diseases in exposed US military veterans. Ongoing studies at the Vanderbilt University Medical Center and the Nashville VAMC have indicated a correlation in findings between non-invasive XV LVAS lung analysis and open lung biopsies. Software products XV LVAS X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS) is a non-invasive assessment of regional lung motion and airflow. It provides data to generate detailed maps of both the patterns of lung motion and pulmonary function, with functional deficits detected through local (regional) differences in movement. The XV LVAS report analyzes the lungs in three dimensions (3D) over time, during multiple phases of tidal (normal) breathing, resulting in four-dimensional